6:33 PM
 | 
Dec 17, 2012
 |  BC Extra  |  Company News

ViiV Healthcare seeks approval for dolutegravir

ViiV Healthcare Ltd. submitted regulatory applications in the U.S., EU and Canada for dolutegravir to treat HIV infection in patients ages 12 years and older. The submissions include data from the Phase III...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >